603882 Stock Overview
Guangzhou Kingmed Diagnostics Group Co., Ltd. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Guangzhou Kingmed Diagnostics Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥29.46 |
52 Week High | CN¥66.87 |
52 Week Low | CN¥24.61 |
Beta | 0.69 |
1 Month Change | -6.83% |
3 Month Change | -12.27% |
1 Year Change | -51.85% |
3 Year Change | -72.95% |
5 Year Change | -43.22% |
Change since IPO | 31.87% |
Recent News & Updates
Recent updates
Shareholder Returns
603882 | CN Healthcare | CN Market | |
---|---|---|---|
7D | -5.5% | -2.5% | -1.0% |
1Y | -51.8% | -9.2% | 10.8% |
Return vs Industry: 603882 underperformed the CN Healthcare industry which returned -9.2% over the past year.
Return vs Market: 603882 underperformed the CN Market which returned 10.8% over the past year.
Price Volatility
603882 volatility | |
---|---|
603882 Average Weekly Movement | 8.5% |
Healthcare Industry Average Movement | 8.5% |
Market Average Movement | 8.8% |
10% most volatile stocks in CN Market | 13.0% |
10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 603882 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603882's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 11,586 | Yaoming Liang | www.kingmed.com.cn |
Guangzhou Kingmed Diagnostics Group Co., Ltd. provides medical diagnosis services in China. The company also offers clinical research, health management, cold chain logistics, and scientific research services, as well as vitro diagnostics, big data, artificial intelligence, and forensic testing services.
Guangzhou Kingmed Diagnostics Group Co., Ltd. Fundamentals Summary
603882 fundamental statistics | |
---|---|
Market cap | CN¥13.69b |
Earnings (TTM) | CN¥161.20m |
Revenue (TTM) | CN¥7.85b |
84.9x
P/E Ratio1.7x
P/S RatioIs 603882 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603882 income statement (TTM) | |
---|---|
Revenue | CN¥7.85b |
Cost of Revenue | CN¥5.12b |
Gross Profit | CN¥2.73b |
Other Expenses | CN¥2.57b |
Earnings | CN¥161.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.35 |
Gross Margin | 34.76% |
Net Profit Margin | 2.05% |
Debt/Equity Ratio | 7.2% |
How did 603882 perform over the long term?
See historical performance and comparisonDividends
3.0%
Current Dividend Yield255%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 20:45 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangzhou Kingmed Diagnostics Group Co., Ltd. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Hao Wu | Chasing Securities |
Pei Cheng | China Galaxy Securities Co., Ltd. |
Jin Zhang | China International Capital Corporation Limited |